Tenecteplase in the treatment of acute ischemic stroke:a rapid health technology assessment
OBJECTIVE To assess the efficacy,safety and cost-effectiveness of tenecteplase in the treatment of acute ischemic stroke,and to provide a basis for clinical rational drug use and related decision-making.METHODS The related literature in the PubMed,the Cochrane Library,CNKI,Wanfang data and health technology assessment(HTA)databases were searched from the establishment of the database to June 30th,2024.Systematic reviews/meta-analyses,pharmacoeconomic studies and HTA reports on tenecteplase in the treatment of acute ischemic stroke were collected.After data extraction and quality assessment,descriptive analysis of the included studies was carried out.RESULTS A total of 31 articles were included,involving 28 systematic reviews/meta-analysis and 3 pharmacoeconomic studies.In terms of effectiveness,compared with alteplase,tenecteplase(0.25 mg/kg)could significantly increase the early neurological improvement;the 90 d excellent neurological recovery rate,90 d good neurological recovery rate,and recanalization were not inferior to alteplase.For safety,compared with alteplase,tenecteplase did not increase the incidence of hemorrhage,symptomatic intracranial hemorrhage,3-month mortality,or intracranial hemorrhage.In terms of cost-effectiveness,foreign research results showed that tenecteplase had economic advantages over alteplase.CONCLUSIONS Compared with alteplase,tenecteplase is effective and safe in the treatment of acute ischemic stroke,and it is cost-effective.
tenecteplaseacute ischemic strokerapid health technology assessmenteffectivenesssafetycost-effectiveness
万方数据
维普
